Page last updated: 2024-08-22

tiletamine hydrochloride and Sarcoma, Synovial

tiletamine hydrochloride has been researched along with Sarcoma, Synovial in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Horiuchi, K; Kawai, A; Morioka, H; Nakayama, R; Nishimoto, K; Ozaki, T; Sonobe, H; Susa, M; Suzuki, Y; Takaishi, H; Toyama, Y; Umezawa, K; Yabe, H	1

Other Studies

1 other study(ies) available for tiletamine hydrochloride and Sarcoma, Synovial

Article	Year
Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). Cancer letters, 2008, Dec-18, Volume: 272, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Nucleus; Cyclohexanones; Humans; Microscopy, Confocal; NF-kappa B; Protein Transport; Sarcoma, Synovial	2008

Article

Year

Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).

Cancer letters, 2008, Dec-18, Volume: 272, Issue:2

Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Nucleus; Cyclohexanones; Humans; Microscopy, Confocal; NF-kappa B; Protein Transport; Sarcoma, Synovial

2008